Literature DB >> 20100088

Effect of the neuraminidase mutation H274Y conferring resistance to oseltamivir on the replicative capacity and virulence of old and recent human influenza A(H1N1) viruses.

Mariana Baz1, Yacine Abed, Philippe Simon, Marie-Eve Hamelin, Guy Boivin.   

Abstract

BACKGROUND: The viral fitness of neuraminidase inhibitor (NAI)-resistant influenza viruses is believed to be impaired. Unexpectedly, an oseltamivir-resistant A(H1N1) variant containing the H274Y neuraminidase (NA) mutation recently disseminated worldwide, suggesting that the replication and virulence properties of this mutant virus were not compromised.
METHODS: In vitro replicative capacities were determined for old (A/WSN/33, A/Mississipi/3/01, A/New Caledonia/20/99, and A/Solomon Islands/03/06) and recent (A/Brisbane/59/2007-like) influenza A(H1N1) viruses either harboring or not harboring the H274Y NA mutation. Ferrets were infected with the A/Brisbane/59/2007-like wild-type (WT) isolate and its H274Y NA variant.
RESULTS: Old A(H1N1) WT viruses grew at higher titers than did the A/Brisbane/59/2007-like viruses in vitro. The H274Y mutation was associated with reduced viral plaque areas in cells infected with A/WSN/33 and A/Mississippi/3/01, whereas the 2 A/Brisbane/59/2007-like isolates showed similar plaque sizes. In ferrets, the pyrexic response induced by the A/Brisbane/59/2007-like H274Y mutant was significantly higher than that induced by the WT isolate. Nasal wash viral titers were significantly greater for the mutant isolate on day 2 after inoculation, whereas the 2 viruses showed similar titers between days 3 and 7 after inoculation.
CONCLUSIONS: The viral fitness of the recent A/Brisbane/59/2007-like H274Y variant is not impaired, consistent with its global dissemination. These results reinforce the need for new antiviral strategies.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20100088     DOI: 10.1086/650464

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  64 in total

1.  Enhanced mammalian transmissibility of seasonal influenza A/H1N1 viruses encoding an oseltamivir-resistant neuraminidase.

Authors:  Nicole M Bouvier; Saad Rahmat; Natalie Pica
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

2.  Characterization of drug-resistant influenza virus A(H1N1) and A(H3N2) variants selected in vitro with laninamivir.

Authors:  Mélanie Samson; Yacine Abed; François-Marc Desrochers; Stephanie Hamilton; Angela Luttick; Simon P Tucker; Melinda J Pryor; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

3.  The global spread of drug-resistant influenza.

Authors:  Dennis L Chao; Jesse D Bloom; Beth F Kochin; Rustom Antia; Ira M Longini
Journal:  J R Soc Interface       Date:  2011-08-24       Impact factor: 4.118

Review 4.  Fitness of neuraminidase inhibitor-resistant influenza A viruses.

Authors:  Tatiana Baranovich; Robert G Webster; Elena A Govorkova
Journal:  Curr Opin Virol       Date:  2011-10-01       Impact factor: 7.090

5.  The H275Y neuraminidase mutation of the pandemic A/H1N1 influenza virus lengthens the eclipse phase and reduces viral output of infected cells, potentially compromising fitness in ferrets.

Authors:  Lady Tatiana Pinilla; Benjamin P Holder; Yacine Abed; Guy Boivin; Catherine A A Beauchemin
Journal:  J Virol       Date:  2012-07-25       Impact factor: 5.103

6.  Evaluation of recombinant 2009 pandemic influenza A (H1N1) viruses harboring zanamivir resistance mutations in mice and ferrets.

Authors:  Andrés Pizzorno; Yacine Abed; Chantal Rhéaume; Xavier Bouhy; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2013-01-28       Impact factor: 5.191

7.  Treatment of oseltamivir-resistant influenza A (H1N1) virus infections in mice with antiviral agents.

Authors:  Donald F Smee; Justin G Julander; E Bart Tarbet; Matthew Gross; Jack Nguyen
Journal:  Antiviral Res       Date:  2012-07-15       Impact factor: 5.970

8.  Comparable fitness and transmissibility between oseltamivir-resistant pandemic 2009 and seasonal H1N1 influenza viruses with the H275Y neuraminidase mutation.

Authors:  Diana D Y Wong; Ka-Tim Choy; Renee W Y Chan; Sin Fun Sia; Hsin-Ping Chiu; Peter P H Cheung; Michael C W Chan; J S Malik Peiris; Hui-Ling Yen
Journal:  J Virol       Date:  2012-07-18       Impact factor: 5.103

9.  Characterization of drug-resistant influenza A(H7N9) variants isolated from an oseltamivir-treated patient in Taiwan.

Authors:  Henju Marjuki; Vasiliy P Mishin; Anton P Chesnokov; Joyce Jones; Juan A De La Cruz; Katrina Sleeman; Daisuke Tamura; Ha T Nguyen; Ho-Sheng Wu; Feng-Yee Chang; Ming-Tsan Liu; Alicia M Fry; Nancy J Cox; Julie M Villanueva; Charles T Davis; Larisa V Gubareva
Journal:  J Infect Dis       Date:  2014-08-14       Impact factor: 5.226

10.  New small molecule entry inhibitors targeting hemagglutinin-mediated influenza a virus fusion.

Authors:  Arnab Basu; Aleksandar Antanasijevic; Minxiu Wang; Bing Li; Debra M Mills; Jessica A Ames; Peter J Nash; John D Williams; Norton P Peet; Donald T Moir; Mark N Prichard; Kathy A Keith; Dale L Barnard; Michael Caffrey; Lijun Rong; Terry L Bowlin
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.